Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): Immunomodulation of gene expression

Journal of Autoimmunity

Volumn 33, Issue 1, 2009, Pages 77-82

  Sthoeger, Zev M ^a,b   Sharabi, Amir ^a   Molad, Yair ^c   Asher, Ilan ^b   Zinger, Heidy ^a   Dayan, Molly ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN HOSPITAL   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Immunomodulation of gene expression; Lupus patients; Peptide based treatment; Systemic lupus erythematosus; Tolerogenic peptide

Indexed keywords

B CELL ACTIVATING FACTOR; CASPASE 3; CASPASE 8; EDRATIDE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; PLACEBO; PREDNISONE; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, MONOCLONAL; APOPTOSIS; CASPASES; COMPLEMENTARITY DETERMINING REGIONS; CYTOKINES; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SELF TOLERANCE; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 67349261724     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.03.009     Document Type: Article

References (38)

1. Hahn B.H. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace D.J., and Hahn B.H. (Eds). Dubious' lupus erythematosus (2002), Lippincott Williams & Wilkins, Philadelphia 87-92
2. Nagy G., Koncz A., and Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25 (2005) 123-140
3. Horowitz D.A., and Jacob C.O. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immumopathol 16 (1994) 181-200
4. Segal R., Bermas B.L., Dayan M., Kalush F., Shearer G.M., and Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol 158 (1997) 3009-3016
5. Trébéden-Nègre H., Weill B., Fournier C., and Batteux F. B cell apoptosis accelerates the onset of murine lupus. Eur J Immunol 33 (2003) 1603-1612
6. Emlen W., Niebur J., and Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152 (1994) 3685-3692
7. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
8. Paust S., and Cantor H. Regulatory T cells and autoimmune disease. Immunol Rev 204 (2005) 195-207
9. Sthoeger Z.M., Dayan M., Tcherniack A., Green L., Toledo S., Segal R., et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 131 (2003) 385-392
10. Waisman A., Shoenfeld Y., Blank M., Ruiz P.J., and Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol 7 (1995) 689-696
11. Blank M., and Shoenfeld Y. The story of the 16/6 idiotype and systemic lupus erythematosus. Isr Med Assoc J 10 (2008) 37-39
12. Luger D., Dayan M., Zinger H., Liu J.P., and Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 24 (2004) 579-590
13. + cells and TGF-beta. Proc Natl Acad Sci U S A 103 (2006) 8810-8815
14. Parameswaran R, David HB, Sharabi A, Zinger H, Mozes E. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin Immunol, in press. doi:10.1016/j.clim.2008.12.09.
15. Rapoport M.J., Sharabi A., Aharoni D., Bloch O., Zinger H., Dayan M., et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 117 (2005) 262-270
16. Sharabi A., Haviv A., Zinger H., Dayan M., and Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol 119 (2006) 146-155
17. Sharabi A., Luger D., Ben-David H., Dayan M., Zinger H., and Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 179 (2007) 4979-4987
18. Sharabi A., Azulai H., Sthoeger Z.M., and Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 121 (2007) 248-257
19. Sthoeger Z.M., Zinger H., Dekel B., Arditi F., Reisner Y., and Mozes E. Lupus manifestations in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras. J Clin Immunol 23 (2003) 91-99
20. Mauermann N., Sthoeger Z.M., Zinger H., and Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 137 (2004) 513-520
21. Sthoeger Z.M., Sharabi A., Dayan M., Zinger H., Asher I., Sela U., et al. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Hum Immunol 70 (2009) 139-145
22. Tan E.M., Cohen A.S., Fries J.F., Nasi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
23. Gladman D.D., Ibañez D., and Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29 (2002) 288-291
24. Yee C.S., Isenberg D.A., Prabu A., Sokoll K., The L.S., Rahman A., et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 67 (2008) 873-876
25. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166 (2001) 6-10
26. Cheema G.S., Roschke V., Hilbert D.M., and Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44 (2001) 1313-1319
27. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
28. Hahn B.H., Singh R.R., Wong W.K., Tsao B.P., Bulpitt K., and Ebling F.M. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 44 (2001) 432-441
29. Kang H.K., Michaels M.A., Berner B.R., and Datta S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 174 (2005) 3247-3255
30. Stoll M.L., Price K.D., Silvin C.J., Jiang F., and Gavalchin J. Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the (SWR x NZB)F1 murine model. J Autoimmun 29 (2007) 30-37
31. Sela U., Dayan M., Hershkoviz R., Cahalon L., Lider O., and Mozes E. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur J Immunol 36 (2006) 2971-2980
32. Bijl M., Horst G., Limburg P.C., and Kallenberg C.G. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 10 (2001) 866-872
33. Furie R., Stohl W., Ginzler E., Becker M., Mishra N., Chatham W., et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 48 (2003) S377
34. Wallace D.J., Lisse J., Stohl W., Mckay J., Boling F., Merrill J.T., et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks. Arthritis Rheum 54 (2006) S790
35. Torgerson T.R. Regulatory T cells in human autoimmune diseases. Springer Semin Immunopathol 28 (2006) 63-76
36. Lin S.C., Chen K.H., Lin C.H., Kuo C.C., Ling Q.D., and Chan C.H. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest 37 (2007) 987-996
37. + regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity 40 (2007) 521-528
38. Hahn B.H., Anderson M., Le E., and La Cava A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum 58 (2008) 2488-2497